文献速递白血病

博纳吐单抗与化疗在晚期急性淋巴细胞白血病中暴露调整不良事件的比较

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

在3期TOWER研究中,博纳吐单抗较标准治疗化疗在复发或难治性费城染色体阴性B前体急性淋巴细胞白血病成人中显示总生存获益。因两臂治疗暴露不同,探索性分析比较暴露调整事件率,博纳吐单抗组≥3级事件率总体显著低于标准治疗组,但≥3级细胞因子释放综合征事件率更高。

要点

  • 博纳吐单抗组≥3级不良事件暴露调整事件率显著低于标准治疗组(10.73 vs 45.27事件/患者年,P<.001)。
  • 博纳吐单抗组≥3级感染、血细胞减少和神经系统事件暴露调整事件率均显著低于标准治疗组。
  • 博纳吐单抗组≥3级细胞因子释放综合征暴露调整事件率显著高于标准治疗组(0.16 vs 0事件/患者年,P=.038)。

核心结论

  • 博纳吐单抗是复发或难治性费城染色体阴性B前体急性淋巴细胞白血病患者有效且耐受性良好的治疗选择。

研究设计与样本

  • 3期TOWER研究(NCT02013167)的探索性安全性分析,纳入所有接受治疗的患者(安全性人群)。
  • 博纳吐单抗组N=267,中位治疗2周期(范围1-9);标准治疗化疗组N=109,中位治疗1周期(范围1-4)。

主要发现

  • 博纳吐单抗第1周期≥3级不良事件率为76%,第2周期为37%。
  • 博纳吐单抗组≥3级不良事件暴露调整事件率为10.73事件/患者年,标准治疗组为45.27事件/患者年(P<.001)。
  • 博纳吐单抗组≥3级感染暴露调整事件率为1.63事件/患者年,标准治疗组为6.49事件/患者年(P<.001)。
  • 博纳吐单抗组≥3级血细胞减少暴露调整事件率为3.64事件/患者年,标准治疗组为20.07事件/患者年(P<.001)。
  • 博纳吐单抗组≥3级神经系统事件暴露调整事件率为0.38事件/患者年,标准治疗组为0.95事件/患者年(P=.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome-negative (Ph-) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatment arms experienced an adverse event (AE), and the incidence rate of serious AEs was higher for blinatumomab. However, as treatment exposure differed between the 2 arms, we conducted an exploratory safety analysis comparing exposure-adjusted event rates (EAERs) of blinatumomab vs SOC. Analyses were conducted for all patients who received therapy (safety population). Patients received a median (range) of 2 cycles (1-9) of blinatumomab (N = 267) vs 1 cycle (1-4) of SOC (N = 109). Grade ≥3 AE rates were generally higher in cycle 1 of blinatumomab than in cycle 2 (76% vs 37%). After adjusting for time on treatment, EAERs of grade ≥3 were significantly lower for blinatumomab vs SOC overall (10.73 vs 45.27 events per patient-year; P < .001) and for events of clinical interest, including infections (1.63 vs 6.49 events per patient-year; P < .001), cytopenias (3.64 vs 20.07 events per patient-year; P < .001), and neurologic events (0.38 vs 0.95 events per patient-year; P = .008). The EAER of grade ≥3 cytokine-release syndrome was higher for blinatumomab than for SOC (0.16 vs 0 events per patient-year; P = .038). These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for patients with r/r Ph- ALL. This trial was registered at www.clinicaltrials.gov as #NCT02013167.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stein AS, Larson RA, Schuh AC, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018. PMID: 29954814. doi:10.1182/bloodadvances.2018019034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。